Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer

Human Pathology

Volumn 44, Issue 9, 2013, Pages 1766-1772

  Fahmy, Mona ^a   Mansure, Jose Joao ^a   Brimo, Fadi ^b   Yafi, Faysal A ^a   Segal, Robert ^a   Althunayan, Abdulaziz ^a   Hicks, Jessica ^c   Meeker, Alan ^c   Netto, George ^c   Kassouf, Wassim ^a  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

High risk non muscle invasive bladder cancer; mTOR pathway; Prognosis; Tissue microarray

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MEMBRANE PROTEIN; PHOSPHATASE; PROTEIN KINASE B; PROTEIN P27; PROTIEN PS6; TENSIN; TUMOR MARKER; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; SURVIVAL; TISSUE MICROARRAY; TRANSURETHRAL RESECTION; WORSENING FREE SURVIVAL;

HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER; MTOR PATHWAY; PROGNOSIS; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84883465705     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.11.026     Document Type: Article

References (28)

1. A. Jemal Global cancer statistics Cancer J Clin 2011 69 90
2. A.F. Althausen, G.R. Prout, and J.J. Daly Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ J Urol 116 1976 575 580
3. P.-U. Malmström, C. Busch, and B.J. Norlén Recurrence, progression and survival in bladder cancer Scand J Urol Nephrol 21 1987 185 195
4. D. Volanis, T. Kadiyska, and A. Galanis Environmental factors and genetic susceptibility promote urinary bladder cancer Toxicol Lett 193 2010 131 137
5. W. Kassouf, P.E. Spiess, and G.A. Brown Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction J Urol 180 2008 164 167
6. W. Kassouf, P.C. Black, and T. Tuziak Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer J Urol 179 2008 353 358
7. J.A. Garcia, and D. Danielpour Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies Mol Cancer Ther 7 2008 1347 1354
8. G. Viglietto, M.L. Motti, and A. Fusco Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization Cell Cycle 1 2002 394 400
9. D.M. Sabatini mTOR and cancer: insights into a complex relationship Nat Rev Cancer 6 2006 729 734
10. C.H. Sun, Y.H. Chang, and C.C. Pan Activation of the PI3K/AKT/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder Histopathology 58 2011 1054 1063
11. C.N. Qian, K.A. Furge, and J. Knol Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models Cancer Res 69 2009 8256 8264
12. S.B. Edge, D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Greene, and A. Trotti Urinary bladder S.B. Edge, D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Greene, A. Trotti, AJCC Cancer Staging Manual 7th ed. 2010 Springer New York 497 505
13. G. Sauter, F. Algaba, and M. Amin Non-invasive urothelial neoplasias: WHO classification of non-invasive papillary urothelial tumors J.N. Eble, G. Sauder, J.I. Epstein, I.A. Sesterhenn, World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs 2004 IARC Press Lyon 89 157
14. D.L. Lamm, B.A. Blumenstein, and J.D. Crissman Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study J Urol 163 2000 1124 1129
15. S. Huang, and P.J. Houghton Targeting mTOR signaling for cancer therapy Curr Opin Pharmacol 3 2003 371 377
16. J.J. Mansure, R. Nassim, and S. Chevalier Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer Cancer Biol Ther 8 2009 2339 2347
17. L.H. Saal, P. Johansson, and K. Holm Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity Proc Natl Acad Sci U S A 104 2007 7564 7569
18. L.D. Harris, J. De La Cerda, and T. Tuziak Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray Mol Carcinog 47 2008 678 685
19. S. Bose, S. Chandran, J.M. Mirocha, and N. Bose The Akt pathway in human breast cancer: a tissue-array-based analysis Mod Pathol 19 2006 238 245
20. A.R. Tee, D.C. Fingar, and B.D. Manning Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling Proc Natl Acad Sci U S A 99 2002 13571 13576
21. D.D. Sarbassov, D.A. Guertin, S.M. Ali, and D.M. Sabatini Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 2005 1098 1101
22. S.J. Park, T.J. Lee, and I.H. Chang Role of the mTOR pathway in the progression and recurrence of bladder cancer: an immunohistochemical tissue microarray study Korean J Urol 52 2011 466 473
23. I.M. Chu, L. Hengst, and J.M. Slingerland The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy Nat Rev Cancer 8 2008 253 267
24. F. Rabbani, T.M. Koppie, and E. Charytonowicz Prognostic significance of p27Kip1 expression in bladder cancer BJU Int 100 2007 259 263
25. S.F. Shariat, R. Ashfaq, A.I. Sagalowsky, and Y. Lotan Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma J Urol 177 2007 481 487 [discussion 87]
26. L. Schultz, R. Albadine, and J. Hicks Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy Cancer 116 2010 5517 5526
27. X. Zhou, M. Tan, and V. Stone Hawthorne Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers Clin Cancer Res 10 2004 6779 6788
28. A.M. Puzio-Kuter, M. Castillo-Martin, and C.W. Kinkade Inactivation of p53 and Pten promotes invasive bladder cancer Genes Dev 23 2009 675 680